• 'Twincretin' Tirzepatide Gets FDA Approval for Type 2 DiabetesEndocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient

    10 days ago - By Medscape

    Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient accessibility.
    FDA Approvals
    Read more ...

     

  • First GLP-1/GIP Receptor Agonist OK'd for Type 2 Diabetes

    First GLP-1/GIP Receptor Agonist OK'd for Type 2 Diabetes

    10 days ago - By MedPageToday

    The FDA approved first-in-class tirzepatide for patients with type 2 diabetes, the agency announced on Friday.
    Tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist...
    Read more ...

     

  • FDA approves tirzepatide, first dual incretin agonist for type 2 diabetes

    FDA approves tirzepatide, first dual incretin agonist for type 2 diabetes

    10 days ago - By Healio

    The FDA announced it approved the injectable dual incretin agonist tirzepatide to improve glucose response in adults with type 2 diabetes in addition to diet and exercise.
    Tirzepatide is a first-in-class medicine that activates both the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, which leads to improved glucose control. Tirzepatide is injected once weekly, with the dose adjusted as tolerated to meet blood glucose goals.
    “Given the challenges many patients experience in achieving their target blood sugar goals, today's approval of
    Read more ...